Georg Schett

Prof. Dr. Georg Schett is Vice President for Research at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Chair of Internal Medicine III at the University Hospital Erlangen. He has been a leading figure in rheumatology and internal medicine research since joining FAU in 2006, directing the Department of Medicine 3 and shaping FAU's research strategy as a key member of university leadership.

His educational background includes a medical degree from the University of Innsbruck (1994), residency and habilitation in internal medicine at the University of Vienna, and specialized training in rheumatology. He also completed a research fellowship at Amgen, USA.

Georg Schett’s research focuses on rheumatology, autoimmune diseases, inflammation, and translational immunology. His work bridges clinical practice and molecular investigation, aiming to understand disease mechanisms and improve therapeutic outcomes. He has published over 1,000 peer-reviewed articles and maintains an exceptionally high h-index of 155, reflecting significant global impact.

Although specific recent publications are not listed in the source text, his extensive publication record demonstrates sustained contributions across immunology, clinical rheumatology, and molecular pathways of chronic inflammation.

• Scientific Awards:
• Gottfried Wilhelm Leibniz Prize (2023)
• Member, German Academy of Sciences Leopoldina (since 2021)

As Principal Investigator and spokesperson in major third-party funded projects, Prof. Schett has secured substantial research grants and led collaborative initiatives nationally and internationally. He mentors researchers and oversees a large research team, though named students are not listed. His collaborations include institutions such as the Karolinska Institute (Sweden), VIB (Belgium), and the Kennedy Institute of Rheumatology (UK).

He leads the research group at the Department of Medicine 3, University Hospital Erlangen, and is actively involved in national and international scientific networks. His lab focuses on inflammatory diseases with strong translational goals, integrating clinical data with molecular profiling.